Exchange: NASDAQ·Updated 07:30 PM EST
ALMS logo

ALMS Alumis Inc.

$4.39
$0.445
(9.19%)
Today
Closed $4.40
$0.005
(0.11%)
After Hours
Reported EarningsNov 12
Mkt Cap$626.47M
Vol2.02M

About ALMS

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
48

Neutral Sentiment

How do you feel about ALMS?

chartistmind
$ALMS banging , 10%+ rocket ripper already but this one ain't leaving my portfolio anytime soon. only leave once 💰➡️💰💰💰
1
6
Kn1fecatche12
$ALMS For some reason this stock has been hovering at levels that would indicate it’s a binary play based on the success or failure of Envu for psoriasis. But Envu didn’t fail its ph3 for psoriasis; to the contrary, it passed with flying colors. The TAM for lupus that did fail ph3 was a drop in the bucket compared to that of psoriasis that succeeded in ph3 and is now waiting for the NDA. This was not some massive ph3 failure all around like EYPT had with Duravyu that led to its 97% drop, bc that company is now on life support and outlook is bleak. It’s the opposite for ALMS with Envu. Time will tell whether the market was correct on the current valuation and R/R, or if this ends up being one of the most massively mistakenly underpriced biotech stocks in the market. I’m firmly in the camp of the latter and think this easily goes 3-4x within a year. Many times the market has been shown to be completely wrong/caught offsides, and this looks to me like one of those times.
8
Kn1fecatche12
$ALMS this is turning into a cautionary tale like many other companies that had potential but failed to act during a selloff. DEFEND YOUR STOCK PRICE WHEN YOU SEE IT SELLING OFF. Don’t let it go into freefall like this, bc if you do, they will keep selling and shorting the life out of the stock until they make it virtually impossible for the company to raise cash at any reasonable valuation later when they need it. If they stay quiet like this I can see it dropping another 10-20% bc it’s losing all technical support levels now. REASSURE INVESTORS WITH POSITIVE NEWS AND DEFEND YOUR STOCK.
3
Freindq
$ALMS this can be acquired at 15-17. The only psoriasis oral drug not with big pharma. NDA any day now.
6
chartistmind
$ALMS I think they are stealing more cheaper. They ain't fooling me. Nobody of importance sold. I am going in for more pain.
4
taotrader
$ALMS With projected Psiorasis revenue alone this is a $25+ stock today. Lupus would have added another $15+ to that. Lupus trial did not go so well. But on Priorasis potential only this seems very undervalued. Am I missing anything?
5
Kn1fecatche12
$ALMS constant accumulation over the last few days off the lows, shorts can sit and watch their gains evaporate. There’s a reason the big boys sold over 20k+ Jan 2027 $7 puts (2M +share equivalent). They made a ton collecting that premium and don’t mind getting exercised bc they’re accumulating everything they can at these levels. All the data about Envu is pointing to a big home run for ALMS. They just need to monetize all that potential ASAP.
5
marti837
$ALMS 1. NDA submission to the FDA – Submission of envudeucitinib for psoriasis, expected in Q4 2026. 2. FDA acceptance of the NDA – Formal acceptance would initiate the regulatory review process and significantly de-risk the drug's path to approval. 3. Strategic partnership or acquisition – A potential deal to commercialize envudeucitinib, or a broader acquisition, could unlock substantial shareholder value.
3
taotrader
$ALMS This price action is absurd! Unless the company is shutting down operations next week? But then why did Insiders buy a bunch at $10 last month?
1
biotechdeeppro
$ALMS I think some good news is coming. I heard the company initiated a blackout period after ER. that is strange. usually it is prior to ER or any significant data readouts.
2
biotechdeeppro
$ALMS I think the reason ALMS is hovering around here, is that market is worried about its cash level and when it is going to raise funding. the last ER it says cash is going to fund into Q4 of 2027. so it will need to raise funding soon, also they may have overburn some cash due to commercial prep etc. they do not have money to start phase 3 or major phase 2 trials, at this moment. so a big dilution is potential coming any time at this price. that is why the stock is not going up. they need to make a deal or something like that to avoid big dilutions, and raise cash for more research or even survival. they cannot do the psoriasis commercial alone. that is the concern.
1
biotechdeeppro
$ALMS the short interest is only 8.7%, since the phase 3 lupus trial failure announced on Sep 01. if people are bearish, would the short interest be like 25% at least? People are selling, but not shorting.
calmwaters2
$ALMS unfortunately this is aggressively being shorted with no end in sight. Filing would have helped but took too long. And any recovery after that may be shot down again. Something is not right.

Advertisement|Remove ads.